 |
 
|
|
Each of the following strategic partners plays a lead role in specific project content areas.
|
|
Masamoto Fujimori, MD, International
A graduate of the University of Shinshu, Medical School, Dr. Fujimori was trained in Neurology and Psychiatry at the University of Tokyo Medical School, where he received a Dr. Med.Sci. before coming to the United States for a Research Fellowship at the University of Minnesota, Medical School. Dr. Fujimori serves as Best Practice Strategic Partner developing relationships with Asian pharmaceutical and biotech companies in the area of drug development.
|
|
|
|
Jerome H. Jaffe, MD, Alcoholism / Substance Abuse
Clinical Professor of Psychiatry, University of Maryland School of Medicine, Baltimore;
Adjunct Professor John Hopkins University School of Hygiene and Public Health. His career in academia and government
spans more than three decades of basic and clinical research, treatment, teaching writing, and policy in the field
of substance abuse. Dr. Jaffe serves as Best Practice strategic partner in post marketing surveillance and risk management
for scheduled drugs including analgesics, stimulants and sedative hypnotics.
|
|
|
|
Sheldon H. Preskorn, MD
Sheldon H. Preskorn, M.D., is President and Chief Executive Officer for the Clinical Research Institute and Professor in the Department of Psychiatry at the University of Kansas School of Medicine-Wichita (KUSM-W).
A fellow of the American Psychiatric Association and the American Psychopathological Association, Dr. Preskorn has served on advisory committees of the Food and Drug Administration, Veterans Administration, National Institutes of Health and National Science Foundation, and was a consultant to the Menninger Foundation on clinical psychopharmacology.
An international lecturer and the author of over 400 scientific, professional articles and books. Dr. Preskorn has received continuous grant funding since 1978 for an estimated life-time total of 50 million dollars. This funding has allowed him to pursue research in psychopharmacology and neuroscience of psychiatric illnesses.
His basic pharmacological and neuroscience research has included studies in learning theory, neurochemistry, neurophysiology, histochemistry, electron microscopy, cerebral blood flow and metabolism, positron emission tomography and radioligand binding.
In his role as President and CEO of Clinical Research Institute (CRI), Dr. Preskorn oversees all operations of this internationally recognized clinical research facility. Under his leadership, CRI conducts phase I-III clinical trials and has a 32-bed clinical research unit where its inpatient studies are conducted as well as a dedicated research clinic where outpatient studies are conducted. More information about CRI can be found at www.cri-research.net.
|
|
|
|
Kate Zhong, MD, MSc, FRCP (C)
A graduate of West China University of Medical Sciences China, Dr. Zhong received her Master Degree in Pharmacology at University of Toronto, she was trained in Psychiatry and became a Fellow of Royal College of Physicians and Surgeons of Canada in 1995. She had a diversified psychiatry practice with extensive experience in CNS clinical research. She joined AstraZeneca in 2001, and has led the world wide Seroquel dementia program, directed clinical trials in schizophrenia and dementia. She has played a key role in supporting the commercial and clinical activities in AZ Asia. After leaving AstraZeneca, she co- founded Global Health Alliance (GHA), an enterprise that focuses on conducting clinical trials in China, providing education on good clinical practices and linking North American and European pharmaceutical companies with strategic partners in China. She is active in numerous professional societies and serves as Executive Consultant to the Deane F. Johnson Center for Neurotherapeutics at UCLA, an academic clinical trials and drug development center.
|
|
|
|
|
